Program
Simvastatin
Also written as “simvastatin”, “ezetimibe (+) simvastatin” and “Fenofibrate/Simvastatin”.
Its studies are mostly in Hypercholesterolemia · Diabetes Mellitus, Type 2 · Hyperlipidemias · Cardiovascular Diseases · Hypertension, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organon | 290 open or running | phase 4since Sep 7, 2005 | Sep 21, 2004 | none ahead |
| Abbott | 80 open or running | phase 3since Mar 25, 2004 | Mar 25, 2004 | none ahead |
| Eli Lilly | 60 open or running | phase 2since Apr 15, 2010 | Apr 15, 2010 | none ahead |
| GlaxoSmithKline | 60 open or running | phase 3since Oct 28, 2005 | Oct 28, 2005 | none ahead |
| Merck | 60 open or running | phase 3since May 24, 2007 | May 24, 2007 | none ahead |
| Pfizer | 40 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Jul 21, 2010 | Jul 21, 2010 | none ahead |
| Biogen | 10 open or running | phase 4since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| entero-therapeutics | 10 open or running | early phase 1since Oct 3, 2016 | Oct 3, 2016 | none ahead |
| Medtronic | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| Viatris | 10 open or running | phase 4since Aug 30, 2005 | Aug 30, 2005 | none ahead |
Also a collaborator on its studies: immunogenics-llc, Regeneron Pharmaceuticals, celerion and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Aug 2, 2005.
- Jul 1, 2010Phase 1 study in Sleep Wake DisordersGlaxoSmithKline · NCT01299597 · 30 enrolled · Germany
- Jul 21, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01167933, NCT01167894
- Apr 13, 2011Phase 3 study in HypercholesterolemiaMerck · NCT01335997 · 1,139 enrolled
- Oct 29, 2011Phase 1 study in Diabetes Mellitus, Type 2Pfizer · NCT01469468 · 14 enrolled · United States
- Jun 26, 2012Phase 3 study in DyslipidemiasAbbott · NCT01674712 · 575 enrolled · Argentina, Czech Republic, Germany and more
- Aug 31, 2012Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT01678820 · 299 enrolled
- Sep 26, 2013Phase 1 study in Lupus Erythematosus, SystemicGlaxoSmithKline · NCT01953835 · 37 enrolled · United States
- Oct 8, 2013Phase 1 study in Healthy VolunteersEli Lilly · NCT01960140 · 40 enrolled · United Kingdom
- May 28, 2014Phase 1 study in Healthy VolunteersEli Lilly · NCT02156492 · 62 enrolled · China
- Nov 20, 2014Phase 1 study in Healthy VolunteersEli Lilly · NCT02300259 · 48 enrolled · United States
- Mar 16, 2016Phase 1 study in DyslipidemiasEli Lilly · NCT02714569 · 60 enrolled · United States
- Oct 3, 2016entero-therapeutics's first study: early phase 1 study in Celiac DiseaseNew to entero-therapeuticsentero-therapeutics · NCT03011931 · 40 enrolled · United States
- Mar 6, 2019Phase 3 study in Hyperlipoproteinemia Type IIOrganon · NCT03884452 · 50 enrolled
- Dec 16, 2023Phase 1 study in ObesityEli Lilly · NCT06186622 · 50 enrolled · United States
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
The newest 60 of 65 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06186622Obesity · United States | 1 | Completed | Eli Lilly | Jul 10, 2024 | 50 |
| NCT03884452Hyperlipoproteinemia Type II | 3 | Completed | Organon | May 24, 2001 | 50 |
| NCT03011931Celiac Disease · United States | Early 1 | Completed | entero-therapeutics | Jan 2019 | 40 |
| NCT02714569Dyslipidemias · United States | 1 | Completed | Eli Lilly | Feb 15, 2017 | 60 |
| NCT02300259Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Apr 2015 | 48 |
| NCT02156492Healthy Volunteers · China | 1 | Completed | Eli Lilly | Dec 2014 | 62 |
| NCT01960140Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Dec 2013 | 40 |
| NCT01953835Lupus Erythematosus, Systemic · United States | 1 | Completed | GlaxoSmithKline | Mar 10, 2014 | 37 |
| NCT01678820Diabetes Mellitus, Type 2 | 3 | Terminated | Merck | Nov 1, 2013 | 299 |
| NCT01674712Dyslipidemias · Argentina, Czech Republic, Germany and more | 3 | Completed | Abbott | Oct 2013 | 575 |
| NCT01469468Diabetes Mellitus, Type 2 · United States | 1 | Completed | Pfizer | Dec 2011 | 14 |
| NCT01335997Hypercholesterolemia | 3 | Terminated | Merck | Jan 1, 2012 | 1,139 |
| NCT01167933Healthy | 1 | Completed | Dr. Reddy's Laboratories | Apr 2005 | 44 |
| NCT01167894Healthy | 1 | Completed | Dr. Reddy's Laboratories | Apr 2005 | 72 |
| NCT01299597Sleep Wake Disorders · Germany | 1 | Completed | GlaxoSmithKline | Feb 26, 2010 | 30 |
| NCT01138072Infections · United States | 1 | Completed | GlaxoSmithKline | Aug 2010 | 14 |
| NCT01105975Dyslipidemias · United States, Denmark, Germany and more | 2 | Completed | Eli Lilly | Jun 2011 | 398 |
| NCT01101568Diabetes Mellitus, Type 2 · United States | 1 | Completed | GlaxoSmithKline | Jun 24, 2010 | 28 |
| NCT00943124Dyslipidemias | 1 | Completed | Merck | Aug 2007 | 220 |
| NCT00935259Hypercholesterolemia | 1 | Completed | Merck | Oct 2009 | 31 |
| NCT00862251Cardiovascular Diseases | 3 | Completed | Organon | Mar 2011 | 808 |
| NCT00739050Lupus Erythematosus, Systemic | 4 | Terminated | Organon | Feb 1, 2008 | 4 |
| NCT00720577Peripheral Arterial Disease | Early 1 | Completed | Medtronic | Jul 2007 | 164 |
| NCT00654628Hypercholesterolemia | 4 | Completed | Organon | Jul 1, 2009 | 173 |
| NCT00653835Hypercholesterolemia | 4 | Completed | Organon | Aug 1, 2004 | 153 |
| NCT00653523Hypercholesterolemia | 3 | Completed | Organon | Jun 1, 2009 | 151 |
| NCT00652301Cholesterol | 3 | Completed | Organon | Apr 2004 | 40 |
| NCT00651560Hyperlipidemias | 3 | Completed | Organon | Dec 23, 2005 | 167 |
| NCT00651391Hypercholesterolemia | 3 | Terminated | Organon | Sep 1, 2004 | 28 |
| NCT00650819Hypercholesterolemia | 3 | Completed | Organon | Feb 1, 2005 | 240 |
| NCT00650663Hypercholesterolemia | 4 | Completed | Organon | Sep 1, 2004 | 247 |
| NCT00566267Hyperlipidemias | 3 | Completed | Merck | 58 | |
| NCT00551447Coronary Disease | 3 | Completed | Organon | Mar 2003 | 616 |
| NCT00504439Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | GlaxoSmithKline | Sep 6, 2007 | 36 |
| NCT00496730Hypercholesterolemia | 3 | Completed | Organon | Aug 2008 | 256 |
| NCT00492765Multiple Sclerosis · Denmark | 4 | Completed | Biogen | Apr 2010 | 380 |
| NCT00479713Hypercholesterolemia | 3 | Completed | Organon | Mar 1, 2008 | 618 |
| NCT00479388Primary Hypercholesterolemia | 3 | Completed | Merck | Jul 2008 | 1,216 |
| NCT00465088Hyperlipidemias · United States | 3 | Completed | Abbott | Feb 2008 | 199 |
| NCT00462748Hypercholesterolemia | 3 | Completed | Organon | Jun 2008 | 786 |
| NCT00442897Hypercholesterolemia | 4 | Completed | Organon | Oct 2008 | 229 |
| NCT00423579Hypercholesterolemia | 4 | Completed | Organon | Mar 1, 2008 | 120 |
| NCT00413972Hypercholesterolemia | 3 | Completed | Organon | Nov 2006 | 392 |
| NCT00409773Hypercholesterolemia | 3 | Completed | Organon | Jul 2008 | 1,143 |
| NCT00398294Hypercholesterolemia · Taiwan | 4 | Completed | Organon | Apr 4, 2006 | 30 |
| NCT00389896HDL Cholesterol | 3 | Completed | Organon | Oct 4, 2002 | 150 |
| NCT00362934Hyperlipidemias · Bulgaria, Czech Republic, Germany and more | 3 | Completed | Abbott | Aug 2008 | 516 |
| NCT00362206Hyperlipidemias · Greece, Israel, Romania and more | 3 | Completed | Abbott | Sep 2008 | 423 |
| NCT00352183Cardiovascular Diseases · Australia, Estonia, Hungary and more | 3 | Completed | Abbott | Aug 2008 | 450 |
| NCT00349375Hyperlipidemias · Czech Republic, Denmark, France and more | 3 | Completed | Abbott | Sep 2008 | 1,040 |
| NCT00271817Hypercholesterolemia | 3 | Completed | Organon | Feb 2008 | 1,220 |
| NCT00267280Hyperlipidemias · United States | 3 | Terminated | Pfizer | Dec 2006 | 640 |
| NCT00267254Hyperlipidemias · United States | 3 | Completed | Pfizer | 640 | |
| NCT00246701Hypertriglyceridemia | 3 | Completed | GlaxoSmithKline | Jun 1, 2006 | 256 |
| NCT00166530Atherosclerosis | 4 | Completed | Organon | Feb 2007 | 367 |
| NCT00166504Hypercholesterolemia | 4 | Completed | Organon | Oct 2007 | 203 |
| NCT00159835Cardiovascular Diseases · Denmark, Finland, Iceland and more | 4 | Completed | Pfizer | 8,600 | |
| NCT00157924Hypercholesterolemia | 4 | Completed | Organon | Sep 2007 | 190 |
| NCT00141141Hypercholesterolemia · Italy | 4 | Completed | Viatris | 383 | |
| NCT00132717Hypercholesterolemia | 3 | Completed | Organon | Jun 1, 2007 | 450 |
How it is read
Names in the registry
- “Simvastatin”, 44 entries
- “simvastatin”, 14 entries
- “ezetimibe (+) simvastatin”, 9 entries
- “Fenofibrate/Simvastatin”, 5 entries
- “Ezetimibe + Simvastatin”, 4 entries
Codes read as this program: MK0733.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 35 studies
- Diabetes Mellitus, Type 2, 9 studies
- Hyperlipidemias, 7 studies
- Cardiovascular Diseases, 3 studies
- Hypertension, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.